Table 2. Patient characteristics at baseline.
| Olanzapine | ||||
|---|---|---|---|---|
| Measure | Placebo (n=9) | 2.5mg (n=6) | 5mg (n=8) | p value |
| Age | 71.3 (6.5) | 70.7 (8.1) | 72.4 (4.8) | 0.882 |
| MMSE | 26 (2.6) | 27 (3.6) | 27 (2.7) | 0.976 |
| BPRS-T | 34.8 (5.9) | 34.3 (5.4) | 33.4 (3) | 0.874 |
| BPRS-P | 7.9 (2) | 9 (3) | 7.8 (2.1) | 0.633 |
| UPDRS, motor
score |
30 (11) | 27.5 (13.1) | 31 (11.6) | 0.855 |
| PDQ-39 | 53 (25.7) | 59 (15.9) | 59 (27.3) | 0.867 |
| BDI | 10.1 (6) | 9.8 (6) | 12.6 (9.2) | 0.738 |
| HAM-D | 8.7 (6.1) | 5.3 (1.6) | 11.6 (7.6) | 0.177 |
| CGI | 4.1 (0.9) | 3.2 (1) | 3.9 (0.8) | 0.161 |
| INS | 4.2 (4) | 4 (2.1) | 2.6 (2.6) | 0.566 |
| HYPINS | 1.5 (1) | 2.3 (1.9) | 2.6 (2.1) | 0.446 |
| SEADL | 76 (15) | 72 (24) | 75 (17) | 0.918 |
Values are given as mean (SD). MMSE, Folstein mini mental test examination; BPRS-T, Brief Psychiatric Rating Scale total score; BPRS-P, psychosis subscale; UPDRS, Unified Parkinson’s Disease Rating Scale; PDQ-39, Parkinson’s disease quality of life questionnaire; BDI, Beck depression inventory; HAM-D, Hamilton depression rating scale; CGI, Clinical global impression; INS, Insomnia score; HYP, Hypersomnia score; SEADL, Schwab-England ADL assessment.